Dexcom’s investigational 15-day continuous glucose monitor has a lower mean absolute relative difference than the current ...

Of the hundreds of millions of people living with diabetes, most liv. Dexcom wants to make sure they have tools to manage it.

EDINBURGH, Scotland, and SAN DIEGO – Tech, not medicine, is the future of care for Type 2 diabetes patients, according to a new report from Dexcom.

Medical device companies presented new data this week at the Advanced Technologies & Treatments for Diabetes conference.

DexCom has been a great trade. While the S&P 500 was flat, the stock price has climbed by 8% to $74.17 per share. This run-up ...

A survey conducted by the continuous glucose monitor maker Dexcom found that just over half of healthcare providers ranked technology and education as having larger impacts when it comes | Dexcom ...

DexCom, Inc. (NASDAQ: DXCM), a global leader in glucose biosensing, today announced the launch of its first multi-region report, the "Dexcom State of Type 2 Report: Access and Attitudes Across Europe ...

DexCom DXCM received a warning letter from ... including the FDA approval of the first over-the-counter CGM in March 2024. Additionally, it has invested in technological advancements, such as ...

This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Treatments for Type 2 diabetes and new clinical trial ...

first-ever accuracy and performance data for Dexcom G7 15 Day,1 will be presented, showcasing an overall mean absolute relative difference (MARD) of 8.0%, making it the most accurate CGM.